ジルベール症候群
出典・脚注

↑  http://www.mayoclinic.com/health/gilberts-syndrome/DS00743
1 2  Dugdale, David C. (2013年5月13日). “Gilbert's disease”. MedlinePlus.   U.S. National Library of Medicine. 2016年6月19日閲覧。
1 2  “Gilbert Syndrome”.   American liver foundation. 2016年6月19日閲覧。
↑  http://www.nhs.uk/conditions/gilbertssyndrome/Pages/Introduction.aspx
1 2  “Gilbert syndrome”.   U.S. National Library of Medicine. 2016年6月19日閲覧。
↑  “Gilbert's syndrome”. Gilbert's (zheel-BAYRZ) syndrome typically is harmless and doesn't require treatment. http://www.cnn.com/HEALTH/library/gilberts-syndrome/DS00743.html
↑  “Gilbert症候群と血液疾患”. 日本小児血液学会雑誌. 6 18:  606. (2004年12月). doi:10.11412/jjph1987.18.6_601. https://doi.org/10.11412/jjph1987.18.6_601.
↑  “Population studies on Gilbert's syndrome”. Journal of Medical Genetics:  152-156. (1975). doi:10.1136/jmg.12.2.152. http://jmg.bmj.com/content/12/2/152.full.pdf.
↑  “クリグラー・ナジャー（Crigler-Najjar）症候群”. 平成28-06-19閲覧。
1 2   New insights in bilirubin metabolism and their clinical implications.. 19. (Oct 2013). p. 6401. doi:10.3748/wjg.v19.i38.6398. PMID 24151358. http://www.wjgnet.com/esps/DownLoadFile.aspx?Type=InPress&FilePath=UserFiles%5CManuscript%5C3411%5CWJG-19-6398.pdf.
↑  Kasper et al., Harrison's Principles of Internal Medicine, 16th edition, McGraw-Hill 2005
↑  Boon et al., Davidson's Principles & Practice of Medicine, 20th edition, Churchill Livingstone 2006
↑  Bancroft JD, Kreamer B, Gourley GR (1998). “Gilbert syndrome accelerates development of neonatal jaundice”. Journal of Pediatrics 132 (4):  656–60. doi:10.1016/S0022-3476(98)70356-7. PMID 9580766.
↑  Cappellini MD, Di Montemuros FM, Sampietro M, Tavazzi D, Fiorelli G (1999). “The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels”. British journal of haematology 104 (4):  928–9. doi:10.1111/j.1365-2141.1999.1331a.x. PMID 10192462.
↑  Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M (2004). “UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer”. Br J Cancer 91 (4):  678–82. doi:10.1038/sj.bjc.6602042. PMC 2364770. PMID 15280927. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364770/.
↑  Rauchschwalbe S, Zuhlsdorf M, Wensing G, Kuhlmann J (2004). “Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype”. Int J Clin Pharmacol Ther 42 (2):  73–7. doi:10.5414/cpp42073. PMID 15180166.
↑  Kohle C, Mohrle B, Munzel PA, Schwab M, Wernet D, Badary OA, Bock KW (2003). “Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians”. Biochem Pharmacol 65 (9):  1521–7. doi:10.1016/S0006-2952(03)00074-1. PMID 12732365.
1 2  Esteban A, Pérez-Mateo M (1999). “Heterogeneity of paracetamol metabolism in Gilbert's syndrome”. European journal of drug metabolism and pharmacokinetics 24 (1):  9–13. doi:10.1007/BF03190005. PMID 10412886.
1 2 3  Gilbert Syndrome - eMedicine
1 2  Ladislav Novotnýc and Libor Vítek (2003). “Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies”. Experimental Biology and Medicine 228 (5):  568–571. PMID 12709588.
↑  Schwertner Harvey A; Vítek Libor (2008). “Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin”. Atherosclerosis 198 (1):  1–11. doi:10.1016/j.atherosclerosis.2008.01.001. PMID 18343383.
1 2  Vítek L, Jirsa M, Brodanová M, and others (2002). “Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels”. Atherosclerosis 160 (2):  449–56. doi:10.1016/S0021-9150(01)00601-3. PMID 11849670. http://linkinghub.elsevier.com/retrieve/pii/S0021915001006013.
↑  Lin JP, O’Donnell CJ, Schwaiger JP, and others (2006). “Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study”. Circulation 114 (14):  1476–81. doi:10.1161/CIRCULATIONAHA.106.633206. PMID 17000907.
1 2  GilbertsSyndrome.com
1 2  Olsson R, Bliding A, Jagenburg R, Lapidus L, Larsson B, Svärdsudd K, Wittboldt S. (1988). “Gilbert's syndrome—does it exist? A study of the prevalence of symptoms in Gilbert's syndrome”. Acta Med Scandinavia 224 (5):  485–490. doi:10.1111/j.0954-6820.1988.tb19615.x. PMID 3264448.
↑  Bailey A, Robinson D, Dawson AM. (1977). “Does Gilbert's disease exist?”. Lancet 1 (8018):  931–3. doi:10.1016/S0140-6736(77)92226-7. PMID 67389.
↑  Larissa K. F. Temple, Robin S. McLeod, Steven Gallinger, James G. Wright (2001). “Defining Disease in the Genomics Era”. Science Magazine 293 (5531):  807–808. doi:10.1126/science.1062938. PMID 11486074.
↑  del Giudice EM, Perrotta S, Nobili B, Specchia C, d'Urzo G, Iolascon A (October 1999). “Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis”. Blood 94 (7):  2259–62. PMID 10498597. http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=10498597.
↑  Horsfall LJ, Nazareth I, Pereira SP, Petersen I. (2013 Oct;28). “Gilbert's syndrome and the risk of death: a population-based cohort study.”. Journal of Gastroenterology and Hepatology 28 (10):  1643–1647. PMID 23701650. http://www.ncbi.nlm.nih.gov/pubmed/23701650?dopt=Abstract.
↑   “Entrez Gene: UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1” (English) (2014年9月). 2014年9月6日閲覧。
↑  Raijmakers MT, Jansen PL, Steegers EA, Peters WH (2000). “Association of human liver bilirubin UDP-glucuronyltransferase activity, most commonly due to a polymorphism in the promoter region of the UGT1A1 gene”. Journal of Hepatology 33 (3):  348–351. doi:10.1016/S0168-8278(00)80268-8. PMID 11019988.
1 2  Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN et al. (1995). “The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome”. New England Journal of Medicine 333 (18):  1171–5. doi:10.1056/NEJM199511023331802. PMID 7565971.
↑  Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996). “Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome”. Lancet 347 (9001):  578–81. doi:10.1016/S0140-6736(96)91273-8. PMID 8596320.
↑  J L Gollan, C Bateman, B H Billing (1976). “Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome”. Gut 17 (5):  335–340. doi:10.1136/gut.17.5.335. PMC 1411132. PMID 1278716. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1411132/.
↑  N Carulli, M Ponz de Leon, E Mauro, F Manenti, A Ferrari (1976). “Alteration of drug metabolism in Gilbert's syndrome”. Gut 17 (8):  581–587. doi:10.1136/gut.17.8.581. PMC 1411334. PMID 976795. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1411334/.
↑  “Metabolomic pattern of people with Gilbert's syndrome” (2012年). 2016年12月11日閲覧。
↑  Gilbert's syndrome - Who Named It?
↑  Gilbert A, Lereboullet P (1901). “La cholemie simple familiale”. Sem Med 21:  241–3.
↑  Jens Einar Meulengracht - Who Named It?
↑  Foulk, WT; Butt, HR; Owen, CA, Jr; Whitcomb, FF, Jr; Mason, HL (1959). “Constitutional hepatic dysfunction (Gilbert's disease): its natural history and related syndromes”. Medicine (Baltimore) 38 (1):  25–46. PMID 13632313.
↑  Shmaefsky, Brian (2006). “5”. Biotechnology 101. Greenwood Publishing Group. pp. 175. ISBN 978-0-313-33528-0. https://books.google.co.jp/books?id=E4KhutqTYNAC&pg=PA175&lpg=PA175&dq=%22Arthur+Kornberg%22+gilbert&q=%22Arthur+Kornberg%22+gilbert&redir_esc=y&hl=ja
1 2  “Wire preaches delights of three cliffs”. South Wales Evening Post:  pp. 3. (2007年4月27日)
↑  Bodo, Pete. “Blood Simple”.   tennis.com. 27 May 2011閲覧。
↑  Thornton, M. (3 July 2009). “How our last Final hero, Henry 'Bunny' Austin, became an outcast for 40 years”. Daily Mail (London). http://www.dailymail.co.uk/news/article-1197221/How-Final-hero-Henry-Bunny-Austin-outcast-40-years.html